Basilea Pharmaceutica Ltd.’s fibroblast growth factor receptor (FGFR) kinase inhibitor, derazantinib, also acts as an inhibitor at the colony-stimulating factor-1 receptor (CSF1R), and this activity may differentiate the candidate anticancer from other FGFR kinase inhibitors, the company claims.
Preclinical studies of derazantinib suggest CSF1R inhibition may lead to enhanced clinical responses to checkpoint inhibitors, executives from the Basel,...






